Pfizer and Novo Nordisk are in a heated legal and bidding war over Metsera, an obesity drug developer. Novo's $10 billion bid ...
Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback